Compare Global X Copper Miners ETF (COPX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs ResMed Inc. — how do they compare? Global X Copper Miners ETF trades at $88.56, while ResMed Inc. trades at $225.73 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while Global X Copper Miners ETF pays none, and Global X Copper Miners ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| COPX | RMD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $293.73 |
52-Week Low | $46.08 | $182.82 |
Market Cap | — | $32.61B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $88.51, down 1.12% today, while maintaining a bullish technical outlook with strong moving average signals. The ETF offers exposure to copper miners benefiting from AI-driven demand for electrification infrastructure. Recent institutional buying includes 180 Wealth Advisors increasing its position by 28.1% in Q2 2026 (SEC filing, August 2026). Technical indicators show overbought RSI levels but strong trend momentum with ADX readings.
The copper mining sector faces structural demand growth from AI data center expansion and electrification trends, though mining equities currently trade at a discount to copper futures. Supply constraints and cyclical volatility present risks, but analyst sentiment remains positive for long-term exposure to copper's role in the energy transition.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
